Thrombotic microangiopathy (TMA) associated with pregnancy: role of the clinical laboratory in differential diagnosis
Author:
Ramos Mayordomo Patricia1ORCID, Capilla Díez Marta1, Ticona Espinoza Danay Areli2, Torres Jaramillo María Verónica2, Martínez Tejeda Nathalie2, Ticona Espinoza Thalia Gloria3, Colmenero Calleja Cristina3, Fraile Gutiérrez Virginia3
Affiliation:
1. 16918 Servicio de Análisis Clínicos, Hospital Universitario Río Hortega , Valladolid , Castilla y León , Spain 2. 16918 Servicio de Nefrología, Hospital Universitario Río Hortega , Valladolid , Castilla y León , Spain 3. Servicio de Medicina Intensiva, Hospital Universitario Río Hortega , Valladolid , Castilla y León , Spain
Abstract
Abstract
Objectives
Thrombotic microangiopathy (TMA) is characterized by thrombocytopenia, microangiopathic hemolytic anemia and target organ damage. Pregnancy is associated with several forms of TMA, including preeclampsia (PE), HELLP syndrome, thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). When HUS is secondary to a deregulation of the alternative complement pathway, it is known as atypical HUS (aHUS). Differential diagnosis is challenging, as these forms share clinical characteristics. However, early diagnosis is crucial for a specific treatment to be established and improve prognosis.
Case presentation
We present the case of a 43 year-old primiparous woman admitted to hospital for an urgent C-section at 33 gestational weeks due to a diagnosis of severe preeclampsia and fetal distress. In the immediate postpartum, the patient developed acute liver failure and anuric renal failure in the context of the HELLP syndrome, anemia, thrombocytopenia, arterial hypertension (HTN) and neurological deficit. TMA study and differential diagnosis confirmed pregnancy-associated aHUS. Treatment with eculizumab was initiated, with good response and progressive improvement of clinical and analytical parameters.
Conclusions
aHUS is a rare multifactorial disease that used to be associated with high mortality rates before the advent of eculizumab. Due to challenging diagnosis, the clinical laboratory plays a major role in the differential diagnosis and management of the disease.
Publisher
Walter de Gruyter GmbH
Reference15 articles.
1. Campistol, JM, Arias, M, Ariceta, G, Blasco, M, Espinosa, L, Espinosa, M, et al.. Documento de consenso: actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Nefrología 2015;35:421–47. https://doi.org/10.1016/j.nefro.2015.07.005. 2. Fakhouri, F, Scully, M, Provot, F, Blasco, M, Coppo, P, Noris, M, et al.. Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood 2020;136:2103–17. https://doi.org/10.1182/blood.2020005221. 3. Romero, MA, Orós, D, Vigil-De Gracia, P, Fabre, E. Estados hipertensivos del embarazo, 7th ed. Barcelona, Spain: Elsevier; 2018. 4. Arigita, M, Martínez, GS. Síndrome HELLP: controversias y pronóstico. Hipertens Riesgo Vasc 2020;37:147–51. 5. Sociedad Española de Ginecología y Obstetricia. Guía de Asistencia Práctica: Trastornos hipertensivos en la gestación. Progresos Obstet Ginecol 2020;63:244–72.
|
|